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Chitosan Polysaccharide Suppress Toll Like Receptor Dependent 
Immune Response
Çitosan Polisakkaridi Toll Benzeri Reseptöre Bağlı Bağışıklık Yanıtını Baskılar
Gizem Tincer,1 Banu Bayyurt,1 Yakup M. Arıca,2 İhsan Gürsel1
ABSTRACT
Objectives: Chitosan is a widely used vaccine or anti-cancer delivery vehicle. In this study, we 
investigated the immunomodulatory effect of chitosan/pIC nanocomplexes on mouse immune cells.
Materials and methods: Proliferative and cytotoxic features of chitosan were tested via CCK-8 assay 
on RAW 264.7. IL-1b production was assessed via ELISA from PEC supernatants. TNF-a, and NO 
induction from chitosan treated RAW cells detected by ELISA and Griess assay, respectively. mRNA 
message levels of TLRs and cytokines on macrophages in response to chitosan/pIC nanocomplex 
treatments were evaluated by RT-PCR.
Results: Results revealed that chitosan is non-toxic to cells, however, proliferative capacities of 
macrophages were reduced by chitosan administration. Mouse PECs treated with chitosan, led to NLRP3 
dependent inflammasome activation as evidenced by dose-dependent IL-1b secretion. Chitosan/pIC 
nanocomplexes did not improve immunostimulatory action of pIC on RAW cells, since TNF-a and NO 
productions remained unaltered. Expression levels of several TLRs, CXCL-16 and IFN-a messages from 
mouse splenocytes were down regulated in response to chitosan/pIC nanocomplex treatment.
Conclusion: Our results revealed that chitosan is an anti-proliferative and inflammasome triggering 
macromolecule on immune cells. Utilization of chitosan as a carrier system is of concern for 
immunotherapeutic applications.
Keywords: Biomaterial; chitosan; double-stranded ribonucleic acid; innate immunity; polysaccharide; Toll like 
receptor 3.
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ÖZET
Amaç: Bu çalışmada çitosan/pIC nanokomplekslerinin fare immün hücreleri üzerinde immün 
düzenleyici etkisi araştırıldı.
Gereç ve yöntemler: Çitosanın proliferatif ve sitotoksik özellikleri RAW 264.7’de cell counting 
kit-8 ile test edildi. İnterlökin-1b üretimi ELISA ile peritoneal eksüda hücre süpernatantlarından 
değerlendirildi. Çitosan ile tedavi edilen RAW hücrelerinden tümör nekroz faktör-a ve nitrik oksit 
indüksiyonu sırasıyla ELISA ve Griess testleriyle tespit edildi. Toll benzeri reseptörlerin ribonükleik 
asit mesaj düzeyleri ve çitosan/pIC nanokompleks tedavilerine yanıt olarak makrofajlardaki 
sitokinler ters transkripsiyon polimeraz zincir reaksiyonu ile değerlendirildi.
Bulgular: Bulgular çitosanların hücrelere toksik olmadığını gösterdi; öte yandan, makrofajların 
proliferatif kapasiteleri çitosan uygulaması ile azaltıldı. Çitosan ile tedavi edilen fare peritoneal 
eksüda hücreleri doz bağımlı interlökin-1b sekresyonu ile gösterildiği üzere nükleotid bağlayıcı 
oligomerizasyon domain benzeri reseptör protein 3 bağımlı inflamazom aktivasyonuna yol açtı. Tümör 
nekroz faktör-a ve nitrik oksit üretimleri değişmediğinden, çitosan/pIC nanokompleksleri pIC’nin 
RAW hücreleri üzerindeki immünstimülatör aksiyonunu iyileştirmedi. Toll benzeri reseptörlerin, 
kemokin (C-X-C motif) ligand 16’nın ve interferon-a mesajlarının fare splenositlerinden ifade 
düzeyleri çitosan/pIC nanokompleks tedavilerine yanıt olarak azaldı.
Sonuç: Bulgularımız çitosanın immün hücreler üzerinde antiproliferatif ve inflamazom tetikleyici 
bir makromolekül olduğunu gösterdi. Çitosanın taşıyıcı bir sistem olarak kullanımı immünterapötik 
uygulamaların konusudur.
Anahtar sözcükler: Biyomalzeme; çitosan; çift sarmal ribonükleik asit; doğal bağışıklık; polisakkarit; Toll benzeri 
reseptör 3.
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Chitosan polysaccharides and their derivatives are 
used as adjuvants for mucosal immunity, drug carriers 
and anti-cancer agents.[1] They are widely studied natural 
polysaccharides for the controlled delivery of a drug or an 
adjuvant, as well as a vaccine delivery system. Inclusion of 
chitosan improves the stability of drugs, genes or proteins 
when formulated as micro/nanocarriers.[1-3] 
Lately these biomaterials were used as delivery systems 
for labile Toll-like receptor agonists (TLR) in order to 
improve their immunostimulatory capabilities. When the 
derivatives of chitosan biopolymers were co-administered 
with Toll-like receptor 7 (TLR7) ligand; imiquimod or 
with TLR9 ligand CpG oligodeoxynucleotides (CpG 
ODN), the nanocapsules containing TLR agonists elicited 
a protective immune response against hepatitis B.[4] 
Moreover, when chitosan derivatives were complexed 
with CpG ODN, the uptake of CpG ODNs and the 
cytokine production were improved. As an immune 
adjuvant, chitosan nanoparticles containing CpG ODN 
provoked strong humoral as well as Th1 type cellular 
immune responses in mucosal immunity.[5,6]
Being a valuable biomaterial and an immunotherapeutic 
agent that might be harnessed as a novel drug delivery 
system, the immunomodulatory effects of standalone 
chitosan is still elusive. Chitosan and its derivatives are 
recognized by various types of innate immune receptors, 
Toll-like receptor (TLR) 2, C-type lectin Dectin-1 and the 
mannose receptor, have been implicated in mediating a 
variety of immune responses such as TNF-α, IL-10 and 
IL-17 cytokine production.[7] Moreover, chitosan was 
shown to activate the NLRP3 inflammasome, leading 
to robust IL-1β responses by a phagocytosis-dependent 
mechanism.[8]
In the present study, chitosan derivatives were studied 
to assess their immunostimulatory potential. For this, we 
first checked their cytotoxicity and proliferative effect on 
macrophages. Next, we investigated the inflammasome 
inductive capacity of these biopolymers in the context 
of their IL-1β production potentials from peritoneal 
exudate cells. Furthermore, in order to evaluate the 
immunostimulatory potential of chitosan as a delivery 
system, we nano-complexed chitosan with a TLR3 ligand; 
polyinosinic:polycytidylic acid (pIC) and evaluated the 
TNF-α cytokine and anti-bacterial nitric oxide (NO) 
inductive capacity , along with mRNA message levels 
of different TLRs and type I IFN triggering in mouse 
macrophages.
MATERIALS AND METHODS
All cell culture media components were from Lonza 
(Switzerland) and Hyclone (USA). Cell Counting Kit-8 
(CCK-8) was provided from Dojindo Molecular Devices 
(Japan). Chitosan biopolymer was purchased from Sigma 
Aldrich. TLR3 ligand polyinosinic:polycytidylic acid 
(pIC) was purchased from GE Healthcare Life Sciences. 
Alum was obtained from Thermo Scientific (USA). 
Chitosan complexes with pIC (1:1 w/w, chitosan:ligand 
ratio) were prepared overnight incubation at 4 °C.
Cytotoxicity and proliferation assays
Evaluation of the cytotoxicity and proliferation was 
performed by cell counting kit-8 (CCK-8) assay. RAW 
264.7 cells (mouse macrophage cell line) were distributed 
into 96-well plates as 5000 cell/ml and 105 cell/ml for 
cytotoxicity and proliferation assays, respectively. Cells 
were either incubated with 3 weeks chitosan treated 
(conditioned) media (CM) or with chitosan polymers 
for 24h, 48h and 72h at 37 °C in culture. A total of 100 μl 
of media from each sample was incubated with 10 µl 
CCK-8 in 96-well plate and incubated at 37 °C for 3h. 
Cytotoxicity of chitosan and cell proliferation rate were 
measured as the absorbance at 450 nm using a microplate 
reader (BioTek, µQuant, USA).
Stimulation assays
Peritoneal macrophages from BALB/c mice were 
collected into cold PBS, 4d after intraperitoneal (i.p.) 
injection of 2.5 ml, sterile 4% thioglycollate broth. Cells 
were washed at 1500 rpm for 5 mins and resuspended in 
10% FBS regular RPMI 1640 media. Cells were counted 
with BD AccuriTM C6 (BD, USA) and seeded into plates 
as 1.25x106/ml. Mouse cells were primed with 100 ng/ml 
ultrapure lipopolysaccharide (LPS) for 4h (control cells 
were left unprimed), followed by incubation with the 
positive control alum and chitosan at 20 µg/ml, 100 µg/ml 
and 500 µg/ml doses for 20h. Supernatants were collected 
for IL-1β and TNF-α ELISA assays.
ELISA and NO assays
Immulon 2 HB microtitre plates (Thermo Scientific, 
USA) were coated with anti IL-1β and anti TNF-α 
antibodies (Biolegend, USA) for overnight at 4 °C and 
then blocked with PBS-BSA for 2h @ RT). Serially diluted 
recombinant proteins and culture supernatants were 
transfered into plates for overnight at 4°C. IL-1β and 
TNF-α cytokines were detected using 50 µl biotinylated 
anti-cytokine Ab for 2h (B122: IL-1β and 6B8: TNF-α 
clones, Biolegend, USA) followed by 50 µl phosphatase-
streptavidin (Perbio Pierce, USA) addition for 1h and 
50 µl PNPP substrate addition at RT to develop in the 
wells. The cytokine content was read at 405 nm with 
ELISA plate reader (BioTek, µQuant, USA). Nitric oxide 
detection from RAW 264.7 cells (105/ml) was carried out 
by Griess method, according to manufacturers protocol 
(Fluka, USA). Cells were incubated with the stimulants 
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for 24h and supernatants were read at 540 nm using a 
plate reader.
TLR and cytokine RT-PCR
Total RNA was isolated from 2x106 RAW 264.7 
cells, which were stimulated either with (i) chitosan, 
(ii) pIC and (iii) chitosan/pIC nanocomplexes for 2h 
via TRIzol (Invitrogen, USA) extraction method. 
RNA samples were reverse-transcribed and amplified 
to obtain single stranded cDNA (Finnzymes, Finland). 
cDNA synthesis was performed using 12.5 µl of 
master mix (Finnzymes PCR Master Mix), 1 µl cDNA, 
10 pmol/µl sense and antisense primers specific for 
each target genes. PCR conditions for β-actin, TLR 1, 
2, 3, 4, 6, 7, 9 and CXCL-16 were as follows; 94 °C for 
30 sec, 55 °C for 30 sec, 72 °C, 1 min, 35 cycles, for 
IFN-α; initial denaturation at 94 °C for 2 mins, 94 °C 
for 30 sec, 64.3 °C for 30 sec, 72 °C for 1 min, 40 cycles 
and final extension at 72 °C for 10 mins.
Statistical analyses
Statistical analyses were performed using Sigma 
STAT4 software. Student’s t-test was used to evaluate 
the statistical differences between stimulation groups. P 
values < 0.05 were considered as significant.
RESULTS
Non-toxic chitosan polymer inhibited macrophage 
proliferation
Initial experiments were performed to delineate the 
cytotoxic effects of biopolymer chitosan. For this, RAW 
264.7 cells were stimulated with, (i) 3 weeks polymer 
incubated media or (ii) polymer itself for 1 day, 2 and 
3 days. As seen in the Figure 1a, CCK-8 assay revealed 
that, chitosan did not induce any toxic effect on the 
cells, as evidenced by low absorbance values at 450 nm. 
However, chitosan strongly affected the proliferation of 
macrophages even after the first day of incubation. When 
mouse macrophages were incubated with biopolymer 
conditioned media, similar findings were observed, as 
presented in the Figure 1b. Three weeks old chitosan 
conditioned media negatively affected the proliferation 
capacities of macrophages. These data indicated that, 
chitosan polymer or its by-product leached into culture 
media, were non-toxic, however, they reduced the 
proliferative capacities of mouse macrophages.
Chitosan biopolymer induced inflammasome 
dependent IL-1β production
As shown above, chitosan failed to contribute to 
proliferation rate of mouse macrophages. Whether 
they suppressed TLR dependent immune activation via 
triggering inf lammasome activation was not explored. 
Next, we aimed to investigate these possibilities. 
Thioglycollate treated peritoneal macrophages were 
isolated from BALB/c mice. Cells were primed with 
LPS to initiate pro-IL-1β accumulation and provide 
a substrate for subsequent processing via caspase-1 
leading to mature IL-1β secretion via the assembly 
of inf lammasome multiprotein complexes. After 
4h of priming, cells were incubated with NLRP3 
inf lammasome ligand alum and chitosan in various 
doses for additional 20h. Results showed that, 
chitosan treated peritoneal macrophages released 
IL-1β in a dose dependent manner. The IL-1β levels 
were comparable to alum, a gold standard NLRP3 
inf lammasome ligand (Figure 2). Our data, pointed 
that chitosan could modulate caspase-dependent 
inf lammasome activation. These findings collectively 
(Figures 1 and 2), may explain the low proliferation 
rate induced by chitosan on mouse macrophages, since 
inf lammasome caspase pathway induces pyroptosis 
or necrosis.
(a)
(b)
Figure 1. Effects of chitosan biopolymers on mouse macrophage 
proliferation. (a) RAW 264.7 cells were incubated with 
20 µg/ml chitosan or (b) with 3 weeks chitosan conditioned media 
(Polymer CM) for 24h-72h. Cytotoxic property of biopolymers 
and proliferation status of macrophage cells were detected 
with CCK-8 assay. The results represent mean values from three 
independent experiments ± SD. Student’s t-test revealed that * 
p<0.05.
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Chitosan/pIC nanocomplexes suppressed TLR 
specific message transcripts but did not influence 
cytokine production
Recent reports implicated that when either TLR7 
or TLR9 ligands encapsulated within chitosan 
particles immune stimulatory potentials exceeded 
with respect to their free counterparts.[4-6] Next, 
we aimed to test whether nanocomplexes of TLR3 
ligand, pIC, with chitosan reproduces this improved 
effect on immune cells. We prepared and tested 
chitosan/pIC nanocomplexes (1:1, w/w) and compared 
immunostimulatory activity to that of free pIC on 
immune cells. When RAW 264.7 cells incubated with 
pIC, chitosan alone or their complexed forms for 24h in 
culture, ELISA results demonstrated that chitosan/pIC 
complexes had no substantial positive or negative effect 
on TNF-α secretion compared to pIC alone (Figure 3a). 
Similar to TNF-α cytokine production, complexes did 
not improve NO production compared to pIC treated 
cells in dose dependent manner (Figure 3b). Strikingly, 
as presented in Figure 4a chitosan/pIC complexes 
significantly downregulated TLR 2,3,6,7 and 9 message 
transcipt expressions compared to pIC or chitosan 
alone treated groups. Moreover TLR1 and TLR4 mRNA 
levels in pIC alone treatments were slightly decreased 
compared to chitosan/pIC complexes. Furthermore, 
chitosan downregulated the chemokine CXCL-16 
and IFN-α gene expressions when complexed with 
pIC in contrast to pIC alone after 2h stimulation 
(Figure 4b). Other cytokines and chemokines such as; 
IP-10, MIP3-α and TNF-α were also studied but there 
were no differences among above mentioned treatment 
groups (data not shown).
DISCUSSION
Immunomodulatory activities of chitosan and 
its derivatives have been studied for their potential 
applications against allergy, infectious diseases or 
cancer.[9-11] Previous findings suggested that chitin and 
chitosan induce various pro-inflammatory (IL-1β) or 
inflammatory cytokines (TNF-α, IL-10, IL-17) upon 
incubating them with macrophages or keratinocytes.[12-15]
Present study, established that an analog of dsRNA, 
pIC, that triggers TLR3 mediated signaling cascade failed 
to contribute to improved activity when complexed with 
chitosan and tested on RAW 264.7 cells. While we clearly 
indentified that cytotoxic effect of chitosan on RAW 264.7 
cells were absent, our findings pointed out that in vitro 
proliferation rate of mouse macrophages was negatively 
influenced by chitosan treatment. This reduction is 
not only mediated by chitosan but also regulated by 
the degradation by-products of this biopolymer, since 
macrophages incubated with three weeks old chitosan 
conditioned media significantly diminished proliferation 
of the cells.
Figure 2. Inflammasome activation by chitosan were provided 
from mouse PECs. Quantification of IL-1β production with 
4h LPS (100 ng/ml) priming prior to stimulation of BALB/c 
PECs with chitosan (20 µg/ml, 100 µg/ml, 500 µg/ml) and as 
positive control with alum (20 µg/ml, 100 µg/ml, 500 µg/ml) for 
18h. Representative plots of three independent experiments 
are shown. p<0.01 between untreated and chitosan (except 
20 µg/ml) treated groups.
Figure 3. Dose dependent TNF-α and NO production were provided 
from mouse macrophages with pIC, chitosan and chitosan+pIC 
complexes (a) TNF-α and (b) NO levels were detected by ELISA and 
Griess assay respectively from from RAW cell supernatants after 
24h stimulation. Result represents combination of at least two 
independent experiments.
(a)
(b)
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Natural biomaterials like chitosan have been 
demonstrated to induce NLRP3 inf lammasome 
dependent IL-1β production in bone marrow derived 
macrophages.[14] Regarding to the anti-proliferative effect 
of chitosan, we aimed to investigate the inflammasome 
dependent IL-1β production in peritoneal mouse 
macrophages. LPS primed macrophages induced more 
IL-1β production upon chitosan stimulation. This 
production was parallel to alum, one of the well-
established NLRP3 ligands (Figure 2). High levels of 
IL-1β release from macrophages could be attributed to 
the cell death and anti-proliferative effect of chitosan.
The most extensively studied pathogen recognition 
receptors (PRRs) are TLRs. They recognize specific 
pathogen associated molecular patterns (PAMPs).[16] 
A subclass of TLRs are also known as, endosome associated 
TLRs. These are TLR3, 7/8 and 9. They are specialized to 
sense pathogenic nucleic acid moieties.[17] TLR3 detects 
double stranded RNA, or synthetic poly (inosinic: 
cytidylic acid; pIC) and used as immunotherapeutic 
agent.[18] When these ligands are given in vivo, they are 
rapidly cleared by nucleases, decreasing their therapeutic 
effects.[19] Various carrier systems such as liposomes, 
biodegradable carriers and soluble macromolecules were 
widely studied for labile nucleic acids attempting to 
increase their in vivo performances.[20-22]
Although numerous studies investigated chitosan 
as a delivery and drug carrier systems for proteins 
plasmids and peptides, there are only few studies in 
the literature aiming to develop chitosan as delivery 
system for labile nucleic acid based TLR ligands. 
Co-delivery of TLR7 agonist, imiquimod and the 
recombinant hepatitis B surface antigen with chitosan 
resulted improved protective immune response and 
immunological memory.[4] A recent study demonstrated 
that, chitosan-CpG ODN carrier system synergistically 
promoted the secretion of Th1 and Th17 dependent 
cell polarizing cytokines from mouse dendritic 
cells.[23] Chitosan-silica-CpG ODN nanohybrids 
enhanced cellular uptake and induction of IL-6 to a 
greater degree than chitosan/CpG ODN nanocomplexes 
in human peripheral blood mononuclear cells.[5]
In light of the recently accumulated data, our goal 
was to develop a chitosan/pIC nano delivery system and 
expand its beneficial immunotherapeutic applications. 
When complexes were assayed, we found that, nano-
formulations did not improve TNF-α production in a 
dose-dependent manner compared to pIC or chitosan 
alone treated cells (Figure 3a). We further assessed 
the production of macrophage mediated anti-bacterial 
cytotoxic effect by checking NO production and 
found that there was no improvement in NO secretion 
(Figure 3b). Surprisingly, chitosan/pIC complexes, 
downregulated the mRNA levels of TLR 1, 2, 3, 4, 6, 7 
and 9 compared to the pIC alone treated RAW 264.7 
mouse macrophages. Moreover, gene expression levels 
of scavenger receptor CXCL-16 and anti-viral Type I 
interferon alpha were also down-regulated (Figure 4). 
Contrary to the previous findings reported with TLR7/8 
and TLR9 ligands, chitosan/pIC complexes failed to 
develop a Th1 based inflammatory response. However, 
parallel studies of chitosan + TLR7/8 agonist; R848 or 
gardiquimod, TLR9 agonist; CpG ODN complexes along 
with pIC (TLR3 ligand) should be performed in order 
to prove that TLR7/8 and TLR9 ligands synergize with 
chitosan, while TLR3 failed to reproduce similar effects.
Figure 4. TLR and cytokine gene expression profile of chitosan 
and pIC. mRNA levels of (a) TLRs, (b) CXCL-16 and IFN-α were 
assessed by reverse transcriptase PCR from chitosan (20 µg/ml), 
pIC (20 µg/ml) and chitosan/pIC (20 µg/ml:20 µg/ml) treated RAW 
264.7 cells after 2h in vitro incubation.
(a)
(b)
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In conclusion, the non-toxic, anti-proliferative 
chitosan showed inflammasome dependent inflammatory 
response, yet did not improve immunostimulatory effect 
of associated pIC.
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